Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mariavittoria Locci et al.|The Breast|2018Cited by 35
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patientsAnna Crispo, Grazia Arpino, Livia S. A. Augustin et al.|Scientific Reports|2023Cited by 20
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Carmen Criscitiello, Stefania Morganti et al.|JAMA Network Open|2025Cited by 11
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analoguesAlessandro Conforti, Carlo Alviggi, Francesco Schettini et al.|The Breast Journal|2019Cited by 7
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|EClinicalMedicine|2025Cited by 7